Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock (RESCUE HF-CS)

A Randomized, Double-blind, Phase 2b/3 Clinical Study of Istaroxime Combined With Standard Care Versus Placebo and Standard of Care for the Treatment of Cardiogenic Shock (CS) Society for Cardiovascular Angiography and Interventions (SCAI) Stage B or C Due to Acute Heart Failure (AHF)

The goal of this clinical trial is to learn if the drug istaroxime works to treat mild to moderate cardiogenic shock due to acute heart failure in adults. It will also learn about the safety of istaroxime. The main questions it aims to answer are:

• Does istaroxime relieve participants' shortness of breath compared to a placebo?
• Does istaroxime provide clinical benefit in terms of lowering the risk of dying, having invasive procedures, having worsening heart failure, and/or increasing quality of life compared to a placebo?
• Does istaroxime increase blood pressure compared to a placebo? Researchers will compare istaroxime to a placebo (a look-alike substance that contains no drug) to see if istaroxime works to treat mild to moderate cardiogenic shock due to acute heart failure.

Participants will:

• Receive a 48-hour intravenous infusion of istaroxime or placebo
• Complete questionnaires rating their breathing and describing their quality of life
• Return for a visit 30 and 90 days after the initial drug infusion was started

Study Overview

• Status: Not yet recruiting
• Conditions: Cardiogenic Shock
• Intervention / Treatment: Drug: istaroxime; Drug: placebo

• Study Type: Interventional
• Enrollment (Estimated): 600
• Phase: Phase 2; Phase 3

Contacts and Locations

• Study Contact: Name: Gad Cotter MD, MD; Phone Number: 9195990939; Email: gadcotter@seismicrx.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Aged between 18 and 80 years old (inclusive) at the time of informed consent, regardless of gender.

2. Diagnosed with CS SCAI B or C due to AHF during screening, before randomization, as defined by:

   1. Dyspnea at rest or with minimal activity before screening and randomization.
   2. Pulmonary rales, or lower limb edema by physical examination.
   3. Evidence of pulmonary congestion by chest X-ray, CT scan or lung ultrasound

   4. At the time of screening and just prior to randomization either:

      1. systolic BP ≤ 100 mmHg or
      2. systolic BP ≤ 115 mmHg and >100 mmHg accompanied by at least one sign of hypoperfusion or hemodynamic compromise: cool extremities, altered mentation attributable to low output, oliguria, elevated lactate (>2 mmol/L), worsening renal function attributable to low perfusion, or invasive/noninvasive hemodynamic evidence of reduced cardiac output.
3. Admitted for AHF within 20 hours before randomization.
4. Documented history within 6 months prior to screening, or during the current admission, of left ventricular ejection fraction (LVEF) < 40%.
5. New York Heart Association (NYHA) functional class ≥ II at 1 month prior to admission.
6. N-terminal pro-B-type natriuretic peptide (NT-proBNP) > 1,500 pg/mL or BNP > 400 pg/mL during screening, before randomization.
7. Signed informed consent as described in Section 11.3 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria:

1. Body weight < 40 kg or ≥ 150 kg at Screening.
2. Society for Cardiovascular Angiography and Interventions (SCAI) level D or more severe cardiogenic shock during screening, prior to randomization.
3. Patients with any systolic blood pressure measurement >130 mmHg within 2 hours prior to randomization.
4. Administration during the 6 hours prior to screening of vasodilators such as nitroglycerin, nitrates, recombinant human brain natriuretic peptide
5. Prescription of digoxin within 7 days before randomization.
6. Patients with severe lung disease (dependent on oral steroids or immunosuppressive therapy or require home oxygen therapy), respiratory failure, or severe pulmonary hypertension.
7. Acute ischemic or hemorrhagic cerebral infarction or transient ischemic attack within 30 days before screening.

8. Abnormal laboratory findings including during screening:

   1. Renal impairment (eGFR < 25 ml/min/1.73 m2) or the need for long-term or intermittent renal support therapy (hemodialysis, ultrafiltration or peritoneal dialysis);
   2. Severe electrolyte imbalance (Na+ <120mmol/L or >160mmol/L, and/or K+ <3.2mmol/L or >5.5mmol/L);
   3. Liver function impairment (ALT and/or AST > 3 times the upper limit of the normal range and/or bilirubin exceeds 1.5 times the upper limit of the normal range);
   4. Hemoglobin <9 g/dL (<5.6 mmol/L).
9. Severe valvular stenosis that has not been surgically corrected, or moderate or severe aortic or pulmonary regurgitation.
10. Obstructive hypertrophic cardiomyopathy or restrictive cardiomyopathy, constrictive pericarditis, cardiac tamponade, cardiomyopathy based on infiltrative disease (such as amyloidosis), accumulation disease (such as hemochromatosis, Fabry disease), myocardial dysplasia, cardiomyopathy caused by reversible causes (such as stress cardiomyopathy) or acute myocarditis.
11. Sustained ventricular tachycardia or ventricular fibrillation within 30 days of screening and randomization.
12. Significant bradycardia (sustained ventricular rate <50 beats per minute), or second or third-degree atrioventricular block (except those using permanent pacemakers).
13. Type 1 acute coronary syndrome (ACS)/myocardial infarction (MI) in the 30 days prior to screening inclusive of the current admission.
14. Patients who have undergone percutaneous coronary angiography or coronary artery bypass grafting or other major cardiovascular surgery including ICD and / or CRT or mechanical support devices within one month before screening, or patients who are expected to require revascularization within three months after screening.
15. Patients on mechanical circulatory support (MCS) during Screening or at the time of randomization.
16. Patients who are expected to require heart transplantation or left ventricular assist during the study period.
17. Patients diagnosed with malignant tumors within 1 year before signing the informed consent form or at the time of screening (excluding fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical surgery, and breast ductal carcinoma in situ after radical surgery), or those undergoing anti-tumor treatment at the time of screening.
18. Patients with diseases that in the opinion of the investigator may lead to mortality within 90 days from randomization.
19. Patients who suffer from severe mental or psychological disorders, cognitive impairment, or a history of mental illness.
20. Patients with known severe allergies or a history of severe drug or food allergic reactions, or those known to be allergic to Istaroxime or its ingredients including lactose.
21. Patients who are pregnant, breastfeeding or planning pregnancy.
22. Patients who cannot be guaranteed to take effective contraceptive measures from the time of signing the informed consent to the 30 days following their last exposure to study drug, or who are of childbearing potential and plan to donate sperm/eggs during this period.
23. Patients of childbearing potential without a negative highly sensitive serum pregnancy test within 24 hours before the first dose of trial intervention.
24. Patients participating in other clinical studies and/or received other study intervention (study drugs or medical devices, etc.) within 30 days before signing the informed consent form, or who are still in the follow up period of other clinical studies.
25. Patients who are unable to comply with all study requirements.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: placebo	Drug: placebo; intravenous placebo
Experimental: istaroxime	Drug: istaroxime; intravenous istaroxime

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in systolic BP		24 hours
composite outcome	Hierarchical composite of death, mechanical circulatory support, worsening heart failure, quality of life assessed using the 'win ratio' method. Quality of life measured on a scale from 0=worst to 100=best. Measured using the percentage of wins among all possible comparisons between patients.	30 days
shortnes of breath	Measured on a scale from 0=worst to 100=best breathing	24 hours

Secondary Outcome Measures

Outcome Measure	Time Frame
lenght of hospital stay	30 days

Collaborators and Investigators

• Sponsor: Seismic Pharmaceuticals Operations LLC

Study record dates

Study Major Dates

• Study Start (Estimated): July 1, 2026
• Primary Completion (Estimated): December 1, 2028
• Study Completion (Estimated): December 1, 2028

Study Registration Dates

• First Submitted: May 1, 2026
• First Submitted That Met QC Criteria: May 7, 2026
• First Posted (Actual): May 13, 2026

Study Record Updates

• Last Update Posted (Actual): May 13, 2026
• Last Update Submitted That Met QC Criteria: May 7, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Pathologic Processes; Heart Diseases; Infarction; Necrosis; Myocardial Ischemia; Myocardial Infarction; Ischemia; Shock; Pathological Conditions, Signs and Symptoms; Shock, Cardiogenic; Istaroxime
• Other Study ID Numbers: Seismic-Ista-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No